Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.
Current Team (14)Update
Past Team (4)Update
Funding Rounds (2) - $98.3MUpdate
Board Members and Advisors (3)Update